Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 20/20 | 0.88 |
| ▸ | CNR2 | P34972 | 19/20 | 0.88 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.76 |
| ▸ | MLNR | O43193 | 1/20 | 0.76 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.76 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.76 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.76 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.76 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.76 |
| ▸ | DRD1 | P21728 | 1/20 | 0.76 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.76 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.76 |
| ▸ | HRH2 | P25021 | 1/20 | 0.76 |
| ▸ | HTR2A | P28223 | 1/20 | 0.76 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.76 |
| ▸ | CCKAR | P32238 | 1/20 | 0.76 |
| ▸ | CCKBR | P32239 | 1/20 | 0.76 |
| ▸ | MC4R | P32245 | 1/20 | 0.76 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1986094 | 1.00 | CNR1 (0.88) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL1985684 | 0.99 | CNR1 (0.88) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL1985825 | 0.94 | CNR1 (1.00) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL1985342 | 0.94 | CNR1 (1.00) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL661779 | 0.93 | CNR1 (1.00) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL1984625 | 0.93 | CNR1 (1.00) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL1985356 | 0.92 | CNR1 (1.00) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL4970000 | 0.92 | CNR1 (0.83) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL1984417 | 0.92 | CNR1 (1.00) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL13078632 | 0.91 | CNR1 (0.82) | CNR1CNR2ABCC4MLNRABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1602656-B1 | PYRAZOLE DERIVATIVES HAVING AFFINITY FOR CB1 AND/OR CB2 RECEPTORS | NEUROSCIENZE PHARMANESS S C A R L (IT) | 2011-06-29 | — | — | EP | claimed |
| US-7659407-B2 | pyrazole derivatives having affinity for cannabinoidergic CB1 and/or CB2 receptors; immune disorders, osteoporosis, renal ischemia, inflammation,transplant rejection; 5-(5-Chloro-thiofen-2-yl)-1-(4-methoxy-phenyl)-4-methyl-1H-pyrazol-3-carboxylic acid | Neuroscienze Pharmaness S.C.a.R.I. (IT) | 2010-02-09 | — | — | US | claimed |
| EP-1602656-A1 | PYRAZOLE DERIVATIVES HAVING AFFINITY FOR CB1 AND/OR CB2 RECEPTORS | NEUROSCIENZE PHARMANESS S.C. a R.L. (IT) | 2005-12-07 | — | — | EP | claimed |
| US-20050261281-A1 | Pharmaceutical compounds | MIDCAP FUNDING III, LLC | 2005-11-24 | — | — | US | claimed |
| US-8227620-B2 | Pharmaceutical compounds | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2012-07-24 | — | — | US | disclosed |
| EP-1602656-B1 | PYRAZOLE DERIVATIVES HAVING AFFINITY FOR CB1 AND/OR CB2 RECEPTORS | NEUROSCIENZE PHARMANESS S C A R L (IT) | 2011-06-29 | — | — | EP | disclosed |
| US-20100105896-A1 | PHARMACEUTICAL COMPOUNDS | Neuroscienze Pharmaness S.C.a.R.I. (IT) | 2010-04-29 | — | — | US | disclosed |
| US-7659407-B2 | pyrazole derivatives having affinity for cannabinoidergic CB1 and/or CB2 receptors; immune disorders, osteoporosis, renal ischemia, inflammation,transplant rejection; 5-(5-Chloro-thiofen-2-yl)-1-(4-methoxy-phenyl)-4-methyl-1H-pyrazol-3-carboxylic acid | Neuroscienze Pharmaness S.C.a.R.I. (IT) | 2010-02-09 | — | — | US | disclosed |
| EP-1602656-A1 | PYRAZOLE DERIVATIVES HAVING AFFINITY FOR CB1 AND/OR CB2 RECEPTORS | NEUROSCIENZE PHARMANESS S.C. a R.L. (IT) | 2005-12-07 | — | — | EP | disclosed |
| US-20050261281-A1 | Pharmaceutical compounds | MIDCAP FUNDING III, LLC | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105896-A1 | PHARMACEUTICAL COMPOUNDS | CNR1, CNR2, OPRD1 | CNR1 1/4885CNR2 2/4885ABCC4 549/4885 |
| US-20050261281-A1 | Pharmaceutical compounds | CNR1, CNR2, OPRD1 | CNR1 1/4885CNR2 2/4885ABCC4 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.